UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                    ----------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): October 26, 2006
                                                         ----------------

                               CYTOGEN CORPORATION
               --------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)


           Delaware                       000-14879              22-2322400
------------------------------    ------------------------   -------------------
 (State or Other Jurisdiction     (Commission File Number)    (I.R.S. Employer
       of Incorporation)                                     Identification No.)


650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
---------------------------------------------------------     ------------------
        (Address of Principal Executive Offices)                  (Zip Code)

       Registrant's telephone number, including area code: (609) 750-8200
                                                           --------------


--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)


     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_|  Written communications  pursuant to Rule 425 under the  Securities Act
(17 CFR 230.425)

     |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
Exchange Act (17 CFR 240.14d-2(b))

     |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
Exchange Act (17 CFR 240.13e-4(c))





ITEM 5.02   DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
            APPOINTMENT  OF  PRINCIPAL  OFFICERS; COMPENSATORY  ARRANGEMENTS  OF
            CERTAIN OFFICERS.

     On October 26, 2006,  Cytogen  Corporation  (the  "Company")  announced the
appointment  of Kevin Bratton as the Company's new chief  financial  officer.  A
finance  executive  with  more  than  35  years  of  experience  in  healthcare,
biotechnology and technology, Mr. Bratton was previously chief financial officer
at Metrologic  Instruments,  Inc. (NASDAQ:  MTLG), a global technology  company.
During his tenure at  Metrologic,  Mr.  Bratton  directed the company's  finance
operations during a period of significant growth in sales, net income, cash flow
from operations, and working capital.

     Prior to joining  Metrologic  Instruments,  Mr.  Bratton  worked at The JPM
Company,  where he served as chief  financial  officer  from 2000 to 2002 and as
director of external  reporting  from 1999 to 2000.  Prior to joining  JPM,  Mr.
Bratton  worked  for more than 20 years in the  healthcare  sector.  He was vice
president  finance and treasurer for the  biotechnology  company IGI,  Inc., and
corporate  controller for the specialty medical company Delmed, Inc. Mr. Bratton
began his career with the public accounting firm Touche Ross & Co. (now Deloitte
& Touche  LLP).  He has a bachelor of science in business  and  accounting  from
Northeastern University.

     The full text of the October 26, 2006 press  release  issued in  connection
with the announcement is attached as Exhibit 99.1 to this Current Report on Form
8-K.

ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

        Exhibit No.       Description
        -----------       -----------

           99.1           Press Release of the Company dated October 26, 2006.





                                   SIGNATURES


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                              CYTOGEN CORPORATION



                                              By: /s/ William J. Thomas
                                                 -------------------------------
                                                 William J. Thomas
                                                 Senior Vice President and
                                                   General Counsel

Dated:   October 26, 2006






                                  EXHIBIT INDEX



        Exhibit No.       Description
        -----------       -----------

           99.1           Press Release of the Company dated October 26, 2006.